Caplyta (Lumateperone Tosylate) Patent Expiration, LOE Window & CMS Spending
Caplyta (Lumateperone Tosylate) by Intra-Cellular Therapies: FDA Orange Book core substance LOE 2029-12-01 (last listed 2040-12-10), 0 AB generics, $595.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Intra-Cellular Therapies |
| FDA Application & Pathway | N209500 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2029-12-01 |
| Last Listed Patent or Exclusivity Date | 2040-12-10 |
| Orange Book Patents (*PED Extensions) | 23 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $595.9M |
| 2024 Medicare Part D Spend | $268.5M |
| 2024 Medicaid Spend | $327.4M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 18.9% 2-yr change) |